The most purchased health supplement by foreigners visiting Korea, “JungKwanJang,” is now available at Sprouts Farmers Market
CERRITOS, Calif., July 23, 2024 /PRNewswire/ -- Customers can now find Korea's representative health supplement brand "JungKwanJang" at the premium market "Sprouts Farmers Market." JungKwanJang is now available at Sprouts Farmers Market! JungKwanJang Red Ginseng boasts superior quality and technology, made with safe ingredients that meet...
Telix Announces A$600 Million Convertible Bonds Offering
MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering of A$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary...
SND Introduces Revolutionary Moderated Drinking Treatment Program
TOKYO, July 23, 2024 /PRNewswire/ -- SND Incorporated (Headquarters: Chiyoda-ku, Tokyo; CEO: Takayuki Hiiragi) is proud to announce the launch of its groundbreaking Moderated Drinking Treatment Program for alcohol dependency. This innovative approach offers a compassionate alternative to traditional abstinence-based treatments, focusing on reducing alcohol consumption rather than complete cessation. The program is now available globally through our comprehensive...
Linical Named Best Global CRO by Global Health & Pharma Magazine
OSAKA, Japan, July 23, 2024 /PRNewswire/ -- Linical, a global Contract Research Organization (CRO) for full-service drug development, has been awarded the title of Best Global CRO 2024 by Global Health & Pharma (GHP) Magazine. The award comes as part of the publication's annual Global Excellence Awards. The 2024 Global Excellence Awards, now...
DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease
Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 23, 2024 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative...
QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs
SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX, a computational drug discovery company, today announced a collaboration with Prelude Therapeutics, a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncology targets. QDX integrates its world-leading quantum mechanical simulation technology, supercomputing, artificial intelligence, and deep drug discovery expertise to advance computational chemistry and drug discovery. Peggy Scherle, PhD, CSO of Prelude,...
Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million
Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol) Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care's commercial platform to grow Movantik volume in the U.S. while reducing gross-to-net and operating costs First quarter financial highlights include revenue growth of 150% and highest-ever EBITDA...
Momcozy Launches Global Campaign to Support Diverse Breastfeeding Journeys This August
NEW YORK, July 22, 2024 /PRNewswire/ -- Global one-stop mother and baby brand Momcozy is launching its "Breaking Barriers - Real Support for Breastfeeding Journeys" campaign. Timed with Worldwide Breastfeeding Week and National Breastfeeding Awareness Month, the initiative aims to empower mothers by addressing common challenges and promoting inclusivity across diverse communities. Momcozy Launches Global Campaign...
Lunit’s AI Solution Enhances Qatar’s National Breast Cancer Screening Program
Middle East's first full-scale AI adoption for national screening marks Lunit's latest milestone amid rapid expansion of global cancer screening initiatives SEOUL, South Korea, July 22, 2024 /PRNewswire/ -- Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the implementation of its AI-powered breast cancer...
Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency
SHANGHAI, July 22, 2024 /PRNewswire/ -- The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovative pharmaceutical company emerging on the international stage, is focused on developing best-in-class pharmaceuticals to improve...
